Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Wells A. Messersmith(University of Colorado Cancer Center), Jeeyun Lee(Samsung Medical Center), Feng Jin, Yung‐Jue Bang(Seoul National University), Philip Fanning, Patricia LoRusso(Yale Cancer Center), Laura Q.M. Chow(The University of Texas at Austin), Won Seog Kim(Samsung Medical Center), Sophia Randolph(Pfizer (United States)), Justin F. Gainor(Harvard University), Tracy C. Kuo(Columbia University), Keun‐Wook Lee(Seoul National University Bundang Hospital), F. Stephen Hodi(Harvard University), Hyun Cheol Chung(Yonsei University), Rafael Santana-Dávila(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hong Wan(Collaborative Drug Discovery (United States)), Jaume Pons, Pierre Squifflet(International Drug Development Institute (Belgium))
Seoul National University Open Repository (Seoul National University)
December 1, 2021
Cited by 95
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k